Millennium announces new chief executive

Millennium Pharmaceuticals has named Deborah Dunsire president and chief executive. Dunsire was previously head of Novartis' North American oncology operations and succeeds Mark Levin, co-founder and chief executive since the Company's inception 12 years ago. Dunsire plans to assume her duties by August 1.
Dunsire said a priority at Millennium would be to strengthen the sales and marketing organization, according to a report in today's New York Times.
Millennium, one of the first companies focusing on genomics, recently shifted gears to developing new drugs rather than searching for genes. The company has two drugs on the market, Integrilin for acute coronary syndrome and Velcade for multiple myeloma. Revenues form sales and alliances were $448 million last year however the company still lost an estimated $252 million.
 
You must be a registered member of MMM to post a comment.

A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.

Email Newsletters


Pharma continues to struggle with its image. Exhibit A is the public debate around the price of, and access to, new and innovative meds. As countless transformative technologies hit market, has industry done enough to anchor its permission to innovate? To provide a closer look at trends affecting trust over the past year, MM&M presents this e-book, "The 2015 Edelman Trust Barometer." Click here.